Sarepta Therapeutics, Inc. (FRA:AB3A)

Market Cap	1.47B +47.6%
Revenue (ttm)	1.89B -2.2%
Net Income	56.42M
EPS	0.55
Shares Out	n/a
PE Ratio	26.14
Forward PE	6.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	13.74
Previous Close	13.90
Day's Range	13.74 - 13.92
52-Week Range	9.84 - 21.42
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 835
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AB3A

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 28, 2026

Data Sources Report a data error